AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04652297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of Placebo
Study NCT04652297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10356
Description: Multiple doses of HS-10356
Study NCT04652297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple doses of Placebo
Study NCT04248153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR55
Description: BR55 will be administered at doses of 0.03 mL/kg or 0.05 mL/kg
Study NCT03657446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan
Description: Continuous i.v. infusion of 20 mg/h or 60 mg/h of clazosentan for 3 h
Study NCT01342042 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rExenatide-4
Description: This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 \[glucagon-like peptide-1\] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.
Study NCT01013259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mutaflor
Description: 1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
Study NCT01013259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule matching the experimental treatment, according to the experimental arm
Study NCT02163356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide/LXS Oral Powder
Description: Oral Powder
Study NCT02163356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Oral Tablet
Study NCT03657446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo infusion
Study NCT03657446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Film-coated tablet containing 400 mg moxifloxacin
Study NCT03397173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered intravenously or subcutaneously at a fixed dose of 75mg/m2/day for 7 consecutive days, allowing interruptions for weekends and holidays within each 28-day cycle. No dose modifications will be permitted during the treatment period.
Study NCT03397173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle. No dose modifications will be permitted during the treatment period.
Study NCT03090841 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bio-specimen collected
Study NCT02098252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurosurgery
Description: Surgical resection to be used when the lesion is considered by a multidisciplinary team to be safely 'operable'.
Study NCT02098252 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: when the AVM is smaller than 3 cm, and considered to not be safely 'operable'.
Study NCT02098252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embolization
Description: Curative embolization, when the lesion is considered curable by embolization.
Study NCT02163356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV
Study NCT02725034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard endoscopy
Study NCT02725034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High definition endoscopy with Optic Enhancement
Study NCT00422097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 5 mg/d
Description: Ixabepilone, 5 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
Study NCT00422097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 10 mg/d
Description: Ixabepilone, 10 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
Study NCT00422097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 15 mg/d
Description: Ixabepilone, 15 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
Study NCT00422097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 20 mg/d
Description: Ixabepilone, 20 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
Study NCT00422097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 25 mg/d
Description: Ixabepilone, 25 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
Study NCT00422097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 30 mg/d
Description: Ixabepilone, 30 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
Study NCT00422097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 25 mg, with famotidine
Description: Participants crossed over from Cycle 1 to receive famotidine, 40 mg, in an oral dose given 2 hours before ixabepilone, 25 mg, on Day 1 of Cycle 2 only.
Study NCT00422097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 25 mg, with food
Description: Participants consume a low-fat meal starting 30 minutes before dose administration on Day 1 of Cycle 2. Food consumed within 30 minutes. Administration of the total oral dose should not exceed more than 10 minutes from start to finish.
Study NCT02572388 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: R21
Study NCT02572388 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Matrix-M1
Study NCT04833673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMR: Progressive Muscle Relaxation
Description: tensing and relaxing the body muscles accompanied with deep breathing
Study NCT04833673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRT:Benson Relaxation Technique
Description: relaxation using mental imagery and mediation
Study NCT00161473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prazosin
Description: Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime.~Duration was 8 weeks.
Study NCT00161473 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (inert substance)
Description: Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.
Study NCT01368978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InsuPatch
Description: device which apply local heating at 38.5 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site.
Study NCT04432207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care chemotherapy
Description: Chemotherapy to be administered according to the prescribing information.
Study NCT01186562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg PO daily
Study NCT01186562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00398073 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mouse gp100 plasmid DNA vaccine
Study NCT00398073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Dermal PowderMed® devices
Study NCT00398073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intramuscularly (IM injection)
Study NCT02304978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group CRC
Description: blood samples
Study NCT02304978 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group control
Description: Blood samples
Study NCT02520453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study NCT02520453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01006369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: hydroxychloroquine 200 mg po BID daily
Study NCT00088699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Study NCT02231918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIRAPEX® - low
Study NCT02231918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIRAPEX® - medium
Study NCT02231918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIRAPEX® - high
Study NCT01568515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electronic Message
Description: Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention \& control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design).
Study NCT06246760 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Incremental exercise test until volitional exhaustion
Study NCT04450888 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The strategic use of messages in risk communication
Description: The interventions in the EMT-OCSP study are strategic health messages delivered (gain-framed vs.loss-framed and long-term vs.short-term contexts) to individuals based on their calculated CVD-free life expectancy and potential interventional benefits.
Study NCT00088699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02120261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Trigger point injection (TPI) with 1 mL of normal saline solution. Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
Study NCT02120261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
Study NCT02120261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Trigger point injection (TPI) with 1 mL of conventional drug mix (lidocaine 1%; 10 mL+ triamcinolone acetonide 40 mg/mL). Trigger point injection involves a single injection in the area of maximal tenderness or trigger point. This will be performed by the treating physician under sterile technique with a 25 gauge needle.
Study NCT04096235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAM Nasal Cannula
Description: The RAM Nasal Cannula is a means of providing CPAP and Bi-PAP to infants 28-42 weeks gestation to prevent nasal septal erosion.
Study NCT03510533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation
Description: blood samples (12ml) and stool samples (30g) collections
Study NCT03510533 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the rates of the autoantibodies directed against the neuropeptides (ghrelin and alpha-MSH) controlling involved in food intake regulation
Description: blood samples (12ml) and stool samples (30g) collections
Study NCT04037644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid loading with Albumin
Description: Fluid loading with 200 ml of 4% Albumin to reverse acute circulatory failure
Study NCT04037644 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid loading with Ringer Lactate
Description: Fluid loading with 5 ml per kg of actual body weight to reverse acute circulatory failure
Study NCT02816112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Antibiotic
Study NCT02816112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupogen
Description: Granulocyte-colony stimulating factor
Study NCT03990038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous perineural infusion of ropivacaine 0.2% 5 ml/h for 48 h
Description: Group C receive the intervention Group U receives the placebo See arm description
Study NCT03990038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Capsule
Description: Group C receives a placebo for extended release hydromorphone Group U receives Hydromorph Contin 3 mg PO BID~See arm description
Study NCT04313452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the effect of Mediterranean diet on insulin sensitivity among obese children and adolescents aged
Description: to find the effect of Mediterranean diet on insulin resistance among obese children and adolescents aged 10-16 years with insulin resistance compared to the regular diet
Study NCT04313452 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: the effect of Mediterranean diet on insulin sensitivity among obese children and adolescents aged
Description: to find the effect of Mediterranean diet on insulin resistance among obese children and adolescents aged 10-16 years with insulin resistance compared to the regular diet
Study NCT02124460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .~The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.~Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study.
Study NCT05367674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Summer Harvest Adventure
Description: Biobehavioral intervention focusing on nutrition and lifestyle behaviors.
Study NCT05367674 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: My Summer Plate (MSP)
Description: My Summer Plate (MSP)
Study NCT03750656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscyamine
Description: Patients will be randomized to receive hyoscyamine for lower urinary tract symptoms are placement of ureteral stent
Study NCT03750656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Patients will be randomized to receive tamsulosin for lower urinary tract symptoms are placement of ureteral stent
Study NCT03226730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Household Visits
Description: Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The relais will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male relais will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
Study NCT03226730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Groups
Description: In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week developed by Pathfinder International and derived from Population Council/UNFPA's Safe Spaces curriculum. The husband groups will follow a curriculum adapted from Promundo's Program P6 and supplemented by the tools and activities developed by Pathfinder International. These groups of husbands will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
Study NCT01149603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate II Ventricular Assist Device
Description: The HeartMate II Left Ventricular Assist Device has been approved by the FDA for use in bridge-to-transplant therapy and destination therapy for patients with endstage heart failure.
Study NCT01096056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2186877A formulation 1
Description: Intramuscular administration, 2 doses
Study NCT01096056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza vaccine GSK2186877A formulation 2
Description: Intramuscular administration, 1 dose
Study NCT01096056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix
Description: Intramuscular administration, 1 dose
Study NCT00198874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Family and Cognitive-Behavioral Therapy
Description: The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
Study NCT00198874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Drug education curriculum was delivered to participants assigned to this condition.
Study NCT03571243 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: observational study
Study NCT00421902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will be have acupuncture (with electro stimulation)
Study NCT02594176 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLEXISEQ®
Description: applicable gel